Oncotarget · 2016 · 45 citations · 34 references
MedicineOncologyPharmacologyCancer PharmacologyMolecular OncologyOncogenesCancer ProgressionMetabolic ReprogrammingOncogene MutationsOncogenic Signaling PathwaysTherapeutic ResistanceTyrosine Kinase InhibitorsGlycolytic PathwaysLung AdenocarcinomaProtein Kinase InhibitorsResistance To Targeted TherapyResistance To Tyrosine Kinase InhibitorsSmall Molecule Tyrosine Kinase InhibitorsTherapeutic Resistance MechanismsTyrosine Kinase Inhibitor Therapy
// Matthew J. Martin 1, 2 , Cath Eberlein 1 , Molly Taylor 1, 2 , Susan Ashton 1 , David Robinson 1, 2 , Darren Cross 1, 2 1 AstraZeneca Oncology, Innovative Medicines, Alderley Park, Macclesfield, Cheshire, United Kingdom 2 AstraZeneca Oncology, Innovative Medicines, CRUK Cambridge Institute, Cambridge, United Kingdom Correspondence to: Matthew J. Martin, email: matthew.j.martin@astrazeneca.com Keywords: non-small cell lung cancer, signal transduction, drug resistance, metabolism, pre-clinical models of drug efficacy Received: March 30, 2016 Accepted: October 31, 2016 Published: November 16, 2016 ABSTRACT Metabolic plasticity is an emerging hallmark of cancer, and increased glycolysis is often observed in transformed cells. Small molecule inhibitors that target driver oncogenes can potentially inhibit the glycolytic pathway. Osimertinib (AZD9291) is a novel EGFR tyrosine kinase inhibitor (TKI) that is potent and selective for sensitising (EGFRm) and T790M resistance mutations. Clinical studies have shown osimertinib to be efficacious in patients with EGFRm/ T790M advanced NSCLC who have progressed after EGFR-TKI treatment. However experience with targeted therapies suggests that acquired resistance may emerge. Thus there is a need to characterize resistance mechanisms and to devise ways to prevent, delay or overcome osimertinib resistance. We show here that osimertinib suppresses glycolysis in parental EGFR-mutant lung adenocarcinoma lines, but has not in osimertinib-resistant cell lines. Critically, we show osimertinib treatment induces a strict dependence on mitochondrial oxidative phosphorylation (OxPhos), as OxPhos inhibitors significantly delay the long-term development of osimertinib resistance in osimertinib-sensitive lines. Accordingly, growth conditions which promote a less glycolytic phenotype confer a degree of osimertinib resistance. Our data support a model in which the combination of osimertinib and OxPhos inhibitors can delay or prevent resistance in osimertinib-naïve tumour cells, and represents a novel strategy that warrants further pre-clinical investigation.
34
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Tony Mok, Yi‐Long Wu, Sumitra Thongprasert et al. · New England Journal of Medicine · 2009 · 8.2K citations · Full text
Medicine, Oncology, Pharmacology +13
Rafael Rosell, Enric Carcereny, Radj Gervais et al. · The Lancet Oncology · 2012 · 5.5K citations · Full text
Medicine, Oncology, Pharmacology +12